

1 Usefulness of the Short Form-8 (SF-8) for chronic pain in the orofacial region

2

3 Aiji Sato (Boku)<sup>1</sup>, Tatsuya Tokura<sup>2\*</sup>, Hiroyuki Kimura<sup>2</sup>, Mikiko Ito<sup>3</sup>, Shinichi Kishi<sup>2</sup>,

4 Takashi Tonoike<sup>4</sup>, Norio Ozaki<sup>2,5</sup>, Yumi Nakano<sup>6</sup>, Saori Nakano<sup>7</sup>, Hiroshi Hoshijima<sup>8</sup>,

5 Masahiro Okuda<sup>1</sup>

6

7

8

9 <sup>1</sup>Department of Anesthesiology, School of Dentistry, Aichi Gakuin University, 2-11

10 Suemori-dori, Chikusa-ku, Nagoya, 464-8651, Japan

11 <sup>2</sup>Department of Psychiatry, Nagoya University Graduate School of Medicine, 65

12 Tsurumai-cho, Showa-ku, Nagoya, 466-8650, Japan

13 <sup>3</sup>Department of Oral and Maxillofacial Surgery, School of Dentistry, Aichi Gakuin

14 University, 2-11 Suemori-dori, Chikusa-ku, Nagoya, 464-8651, Japan

15 <sup>4</sup>Faculty of Psychological and Physical Sciences, Health Service Center, Aichi Gakuin

16 University, 12 Araiike Iwasaki-cho, Nisshin, 470-0195, Japan

17 <sup>5</sup>Institute for Glyco-core Reserch (iGcORE), Nagoya University Graduate School of

18 Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8650, Japan

19 <sup>6</sup>Department of Psychology and Human Relations, Nanan University, 18 Yamazaki-cho,

20 Showa-ku, Nagoya, 466-8673, Japan

21 <sup>7</sup>Aichi PFS Association, 1-21-35 Osu, Naka-ku, Nagoya, 460-0011, Japan

22 <sup>8</sup>Division of Dento-oral Anesthesiology, Tohoku University Graduate School of

23 Dentistry, Seiryomachi 4-1, Aoba-ku, Sendai, 980-0000, Japan

24 \* Corresponding author

25 E-mail: [tatsuyatokura@gmail.com](mailto:tatsuyatokura@gmail.com) (TT)

26

27 All authors contributed equally to this work.

28

29

30

31

32

33

34

35

36

37

38

39

## 40 **Abstract**

41 Given that chronic pain has become a major problem in recent years, affecting  
42 approximately 30% of the general population, this study used the Short Form-8 (SF-8)  
43 Japanese version to investigate (1) the quality of life (QOL) of patients with burning  
44 mouth syndrome (BMS) or persistent idiopathic facial pain (PIFP) (compared to a  
45 Japanese control group) and (2) whether the therapeutic intervention improves the QOL  
46 and reduced pain (comparison between 0 and 12 weeks) of patients with BMS or PIFP.  
47 A total of 63 patients diagnosed with either BMS (n = 45) or PIFP (n = 18) were  
48 included in this study. The diagnostic criteria for BMS and PIFP were established based  
49 on the 3rd edition of the International Classification of Headache Disorders. Our study  
50 results showed that while Physical Component Summary (PCS) in patients with BMS or  
51 PIFP improved with treatment, it did not improve to the national standard value (NSV)  
52 after 12 weeks of intervention. In contrast, Mental Component Summary (MCS)  
53 improved to the same level as NSV after 12 weeks of intervention. Therefore, we found  
54 that therapeutic intervention improves MCS and reduces pain; however, improving PCS  
55 takes time.

56

## 57 **Introduction**

58           Chronic pain has become a major problem in recent years, affecting  
59 approximately 30% of the general population [1]. The majority of these patients are  
60 difficult to treat, and even when they can be treated, 50% of them experience only  
61 partial improvement and reduced quality of life (QOL) [2,3]. However, understanding  
62 chronic pain is difficult; thus, it is underdiagnosed and under-treated because pain  
63 cannot be commensurate with the organic abnormality [4,5]. Chronic pain can be a  
64 comorbidity of mental illness such as depression and can also affect various aspects of  
65 patients' daily lifestyles, such as housework and employment, which immensely lowers  
66 their quality of life [6].

67           Chronic pain in the orofacial region includes various conditions, such as  
68 burning mouth syndrome (BMS), persistent idiopathic facial pain (PIFP), and  
69 nonorganic temporomandibular joint disorder. In particular, BMS and PIFP are  
70 commonly encountered in daily clinical practice [7]. Since these patients often complain  
71 of physical symptoms only, which are the main complaints, establishing an accurate  
72 diagnosis, identifying the treatment, and evaluating the degree of improvement are  
73 difficult even after the treatment intervention.

74           The concept of health-related quality of life (HRQOL) has been generally used  
75   as a multidimensional assessment of how disease and treatment affect a patient’s sense  
76   of overall function and well-being [8]. It is also an inclusive concept based on the  
77   patient’s subjective judgment. In other words, HRQOL quantifies the impact of an  
78   illness on performing activities of daily living (ADL). The Short Form-8 (SF-8) is a  
79   comprehensive, versatile, and practical tool globally used tool for measuring HRQOL  
80   [9], allowing comparison of normative values from large national surveys with results  
81   from more focused outcome studies. The SF-8 is based on the SF-36, a 36-item version  
82   of the rating scale, but is more convenient because it provides results equivalent to the  
83   SF-36. Although the authors provided treatment interventions for many patients with  
84   chronic pain in the orofacial region, pre- and post-treatment evaluations were based on  
85   conventional clinical diagnostic evaluations based on physicians and dentists and were  
86   inadequate from the patient’s viewpoint. In addition to pain reduction, the goal of  
87   treatment is to improve the QOL; however, to the best of the authors’ knowledge, no  
88   previous reports evaluated the QOL at pre- and post-treatment intervention for chronic  
89   pain in the orofacial region.

90           In this study, the SF-8 Japanese version [10] was used to investigate 1) the  
91   QOL of patients with BMS or PIFP (compared to a Japanese control group) and 2)

92 whether the therapeutic intervention improves the QOL and reduced pain (comparison  
93 between 0 and 12 weeks).

## 94 **Materials and methods**

### 95 **Ethical guidelines**

96 This study was conducted per the principles laid out in the Declaration of  
97 Helsinki and was approved by the ethical review committee of Nagoya University  
98 Graduate School of Medicine (no. 234, 234-2, 2004-0234-2 and 2004-0234-3) and the  
99 ethical committee of the School of Dentistry, Aichi Gakuin University (no. 41). Every  
100 effort was made to protect the patients' confidentiality and personal information. All  
101 participants provided written informed consent.

### 102 **Study design and patients**

103 The study was initiated on May 10, 2010 and patients were recruited between  
104 May 10, 2010 and April 21, 2021. A total of 63 patients diagnosed with either BMS (n =  
105 45) or PIFP (n = 18) who were treated at the Liaison Clinic, Department of Oral and  
106 Maxillofacial Surgery, Aichi Gakuin University Dental Hospital (coordinated with the  
107 Department of Psychiatry, Nagoya University Graduate School of Medicine) and who  
108 consented to participate were included in this study. The diagnostic criteria for BMS and

109 PIFP were established based on the 3rd edition of the International Classification of

110 Headache Disorders (Table 1) [11].

111 A trained psychiatrist performed psychiatric evaluations on all patients using

112 the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [12].

113 Patients who visited our liaison clinic before 2013 were diagnosed using the Diagnostic

114 and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision

115 (DSM-IV-TR) [13]. These patients' psychiatric diagnoses were recategorized based on

116 DSM-5 by confirming each patient's clinical record.

117 **Table 1. Diagnostic Criteria of BMS and PIFP Based on the 3rd Edition of the International Classification of Headache Disorder.**

| <b>BMS</b>                                       | <b>PIFP</b>  |
|--|--|
| A. Oral pain fulfilling criteria B and C         | A. Facial and/or oral pain fulfilling criteria B and C                         |
| B. Recurring daily for 2 h per day for >3 months | B. Recurring daily for 2 h per day for >3 months                               |
| C. Pain has the following characteristics:       | C. Pain has the following characteristics:                                     |
| 1. Burning quality                               | 1. Poorly localized and not following the distribution of the peripheral nerve |
| 2. Felt superficially in the oral mucosa         | 2. Dull, aching, or nagging quality  |



D. Oral mucosa is of normal appearance, and clinical examination, including sensory testing, is normal

E. Not better accounted for by another ICHD-3 diagnosis

D. Clinical neurological examination is normal

E. A dental cause has been excluded by appropriate investigations

F. Not better accounted for by another ICHD-3 diagnosis

---

118 BMS, Burning Mouth Syndrome; PIFP, Persistent Idiopathic Facial Pain; ICHD-3, The International Classification of Headache  
119 Disorders 3rd edition  
120

121           To make a psychiatric diagnosis based on DSM-5, a structured clinical  
122 interview was conducted. The psychiatrist and dentist are providing treatment in the  
123 same clinic, and the psychiatric and dental diagnoses were performed in the same place  
124 and at the same time. Regarding therapeutic intervention, serotonin noradrenaline  
125 reuptake inhibitors (SNRIs) are recently more commonly used than tricyclic  
126 antidepressants because of their fewer adverse effects although antidepressants have  
127 been widely used for the treatment of chronic pain. Our previous study reported that  
128 SNRI duloxetine is effective for chronic pain in the orofacial region [14-17]. Based on  
129 the above, duloxetine was also used in the present study and administered to patients  
130 with the above diagnosis from the initial visit (0 weeks). The initial dose of duloxetine  
131 is 20 mg once daily. At  $\geq 2$  weeks after initiating the administration, the dose was  
132 increased to a maximum of 40 mg once daily observing symptom changes and adverse  
133 effect expressions.

134           The collected data were anonymized, and the authors did not have access to  
135 information that could identify individual participants once it was stored.

## 136 **Outcome measures**

137           As the main outcome, for patients who received the therapeutic intervention,  
138 the SF-8 at the initial visit and after 12 weeks of intervention were evaluated and

139 compared with those of the Japanese control participants. The SF-8 consists of the  
140 following items: general health, physical function, daily role function (physical),  
141 physical pain, vitality, social function, mental health, and daily role function (mental)  
142 (Table 2) [9]. These eight items were scored using norm-based scoring (NBS: scoring  
143 based on the national standard value [NSV] [50]) for each item. Based on the eight  
144 items, two summary scores, “Physical Component Summary (PCS)” and “Mental  
145 Component Summary (MCS),” were calculated to indicate physical and mental health,  
146 respectively. For both PCS and MCS, higher scores indicate a higher quality of life. A  
147 group of healthy participants matched in the number with the patient group was also  
148 created from the NBS data and used as the NSV.

149           Additionally, pain intensity was evaluated using a visual analog scale (VAS)  
150 value. To evaluate depression in 63 patients with BMS and PIFP, Beck’s depression  
151 inventory (BDI: cutoff value,  $\leq 10$ ) was used as a subjective index and the Hamilton  
152 depression rating scale (HDRS: cutoff value,  $\leq 7$ ), which uses semi-structured interviews  
153 by a trained psychiatrist, as a highly precise objective index [18,19].

154 **Table 2. Component Concepts and Questions of SF-8.**

---

|  |   |
|--|---|
| <b>1. General health</b>                 | Overall, how has your health been over the past week?   |
| <b>2. Physical function</b>              | In the past month, how often have you been prevented from doing any of the daily activities involving physical exertion (e.g., walking, climbing stairs) by physical reasons? |
| <b>3. Daily role function (physical)</b> | In the past month, how often have you been prevented from doing your usual work (including household chores) due to physical reasons?   |
| <b>4. Physical pain</b>                  | In the past month, how much physical pain have you experienced?   |

---

**5. Vitality**

In the past month, how well have you been?

**6. Social function**

In the past month, how often has your usual social interaction with family and friends

been prevented by physical or psychological reasons?

**7. Mental health**

In the past month, how often have you been suffering from psychological problems

(feeling anxious, depressed, and irritable)?

**8. Daily role function (mental)**

In the past month, how often have your daily activities (such as work, school, and

household chores) been prevented by psychological reasons?

---

155 The score for each item is indicated by a deviation score based on the national standard value (50). In addition, a summary score can be  
156 calculated by multiplying the score of each item by a coefficient summary score. The items closely related to the physical summary  
157 score are 1–4, and the items closely related to the mental summary score are 5–8.

158 SF-8: the Short Form-8

159

## 160 **Statistical analysis**

161 Data are expressed as median (interquartile range [IQR]) or number. Since the  
162 sample size is small and the data do not follow a normal distribution, we adopted the  
163 median value instead of the average value. For statistical testing, the Mann–Whitney  
164 U-test was used to compare differences between two independent groups for continuous  
165 variables. The two-sided statistical significance level was set at  $p \leq 0.05$ . Statistical  
166 analysis of the recorded data was performed using IBM® SPSS® Statistics Ver26.

## 167 **Results**

168 A total of 63 patients participated in the study. Table 3 depicts the demographic  
169 characteristics and psychiatric diagnosis.

170

171 **Table 3. Patient Characteristics in this Study.**

---

|                                      | <b>BMS</b> | <b>PIFP</b>        |
|--------------------------------------|------------|--------------------|
| <b><u>“Patient demographics”</u></b> |            |                    |
| <b>Age (year)</b>                    | 64 [54–70] | 57.5 [51.25–64.75] |

---

| <b>Male/Female</b>  | <b>6/39</b> | <b>1/17</b> |
|---|-------------|-------------|
| <b><u>“Psychiatric diagnosis”</u></b>   |             |             |
| <b>Major depressive disorder</b>  | <b>1</b>    | <b>0</b>    |
| <b>Somatic symptom disorder<br/>with predominant pain</b>                                     | <b>35</b>   | <b>17</b>   |
| <b>Somatic symptom disorder<br/>(other than those above)</b>                                  | <b>2</b>    | <b>0</b>    |
| <b>Major depressive disorder<br/>+ somatic symptom<br/>disorder with<br/>predominant pain</b> | <b>7</b>    | <b>1</b>    |

---

172 Data are expressed as median [interquartile range: IQR] or number.

173 BMS, Burning Mouth Syndrome; PIFP, Persistent Idiopathic Facial Pain



174

175 As shown in Fig 1, the SF-8 PCS was 41.3 [37.1–45.9] at 0 week, 45.3  
176 [40.2–50.1] at 12 weeks, and the NSV was 50.28 [45.86–53.28]. Statistically significant  
177 differences were observed between 0 and 12 weeks, 0 week and NSV, and 12 weeks and  
178 NSV. The SF-8 MCS was 45.4 [38.4–49.6] at 0 week and 48.1 [44.4–52.3] at 12 weeks,  
179 and the NSV was 49.86 [45.96–53.49]. Statistically significant differences were  
180 observed between 0 week and 12 weeks and between 0 week and NSV. However, no  
181 statistically significant difference was observed between 12 weeks and NSV.

182 **Fig 1. Figure 1A. Comparison of SF-8 PCS between at initial visit, after 12 weeks**  
183 **of treatment, and healthy Japanese data.** ※P<0.01 (0week vs 12weeks), ※※  
184 P<0.01 (0week vs NSV), ※※※P<0.01 (12weeks vs NSV)

185 **Figure 1B. Comparison of SF-8 MCS between at initial visit, after 12 weeks of**  
186 **treatment, and healthy Japanese data.** ※P=0.01 (0week vs 12weeks) ※※P<0.01  
187 (0week vs NSV)

188 Fig 2 shows the VAS, BDI, and HDRS between the initial visit and after 12  
189 weeks of treatment. The VAS was 53 [32.5–77] at 0 week and 26 [8.5–46] at 12 weeks.  
190 The BDI was 12 [6.5–18.5] at 0 week and 6 [1.5–10.5] at 12 weeks. The HDRS was 6

191 [3–12] at 0 week and 2 [1–3] at 12 weeks. All parameters showed statistically  
192 significant differences between 0 and 12 weeks.

193 **Fig 2. Figure 2A. Comparison of VAS between at initial visit and after 12 weeks**  
194 **of treatment.** ✖P<0.01 (0week vs 12weeks)

195 **Figure 2B. Comparison of BDI between at initial visit and after 12 weeks of**  
196 **treatment.** ✖P<0.01 (0week vs 12weeks)

197 **Figure 2C. Comparison of HDRS between at initial visit and after 12 weeks of**  
198 **treatment.** ✖P<0.01 (0week vs 12weeks)

199

## 200 **Discussion**

201 This study showed that while PCS in patients with BMS or PIFP improved  
202 with treatment, it did not improve to NSV after 12 weeks of intervention, whereas MCS  
203 improved to the same level as NSV after 12 weeks of intervention. The results  
204 demonstrated that treatment intervention improved BDI and HDRS, a measure of  
205 depression. Emotional factors have been reported to be strongly involved in the  
206 deposition and relief of chronic pain and may have diverse effects on pain expression  
207 [20]. This study indicates that especially when no organic cause has been identified for  
208 physical symptoms, prompt collaboration with psychosomatic medicine and psychiatry

209 is extremely important, rather than making a definitive diagnosis and treatment by  
210 dentistry alone.

211           The validity of the study results is considered high because the SF-8, a standard  
212 and universally used instrument worldwide, was used to measure QOL. Previous reports  
213 using the SF8 have included evaluation for rheumatism [21] and stroke [22], and the  
214 study results indicate that it can be used adequately in the field of dentistry. Visual  
215 assessment methods such as the VAS [23] and the face scale [24] have been previously  
216 used as assessment methods that include patients' mental satisfaction; however, it is  
217 difficult to say that they are sufficient. To evaluate medical interventions, subjective  
218 factors including psychosocial aspects should be measured, and a simple scale is needed  
219 for this purpose. In other words, in addition to the subjective evaluation of physicians  
220 and dentists, improvement of patients' ADL, and tracking the blood data, a scale similar  
221 to the SF8, which easily measures PCS and MCS, can be a good means of  
222 communication between physicians and patients.

223           Although the above findings are similar, MCS recovered while PCS did not  
224 recover to NSV in this study. Thus, emotional turbulence may cause muscle  
225 hyperactivity induced by the central nervous system, resulting in parafunctional habits  
226 [25]. Depression is also reported to be more likely a consequence than a precursor of

227 living with pain so the mind needs to gain supremacy over the body to compensate for  
228 pain. In other words, the emotional side of pain should be managed first, rather than  
229 both the mental and physical sides, and our study may have been the result of  
230 intervention from the mental side. However, restoring PCS is still necessary to improve  
231 the patients' QOL. This may be because many patients do not yet achieve the level  
232 where treatment can be terminated although symptoms tend to decrease after up to 12  
233 weeks of treatment, and treatment for PCS may take a few more weeks to recover to a  
234 level comparable to NSV. One report revealed that it took 2 years for PCS to finally  
235 approach the national norm in a patient with postoperative head and neck cancer [26].  
236 This finding suggests that PCS may not be adequately improved even with long-term  
237 follow-up.

238 MCS improves first due to “the effects of specialized psychiatric treatment  
239 with psychotherapy and antidepressants.”

240 This study has several limitations. First, the number of patients and the study  
241 duration are limited (as noted above, PCS may improve with longer follow-up), and it is  
242 a single-center study. In addition, as the SF-8 is a scale that can be used for a wide range  
243 of patients, from normal participants to patients with chronic diseases, it is not a  
244 disease-specific scale for chronic pain in the orofacial region.

245 In conclusion, we used the SF-8 Japanese version to investigate (1) the QOL of  
246 patients with BMS or PIFP (compared to a Japanese control group) and (2) whether the  
247 therapeutic intervention improves the QOL and pain reduction (comparison between 0  
248 and 12 weeks). The results showed that therapeutic intervention improves MCS and  
249 reduces pain; however, improving PCS takes time.

## 250 **Acknowledgments**

251 The authors would like to thank Enago ([www.enago.jp](http://www.enago.jp)) for the English  
252 language review.

## 253 **References**

- 254 1. Ji RR, Xu ZZ, Gao YJ. Emerging targets in neuroinflammation-driven chronic  
255 pain. *Nat Rev Drug Discov*. 2014;13: 533-48.
- 256 2. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS,  
257 et al. Pharmacologic management of neuropathic pain: evidence-based  
258 recommendations. *Pain*. 2007;132: 237-51.
- 259 3. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological  
260 treatment of neuropathic pain. *Pain*. 2010;150: 573-81.


- 261 4. Murray AM, Toussaint A, Althaus A, Löwe B. The challenge of diagnosing  
262 non-specific, functional, and somatoform disorders: A systematic review of  
263 barriers to diagnosis in primary care. *J Psychosom Res.* 2016;80: 1-10.
- 264 5. Henningsen P, Zipfel S, Herzog W. Management of functional somatic  
265 syndromes. *Lancet.* 2007;369: 946-55.
- 266 6. Turk DC, Wilson HD, Cahana A. Treatment of chronic non-cancer pain. *Lancet.*  
267 2011;377: 2226-35.
- 268 7. Umemura E, Tokura T, Ito M, Kobayashi Y, Tachibana M, Miyauchi T, et al.  
269 Oral medicine psychiatric liaison clinic: study of 1202 patients attending over  
270 an 18-year period. *Int J Oral Maxillofac Surg.* 2019;48: 644-50.
- 271 8. Cella DF. Measuring quality of life in palliative care. *Semin Oncol.* 1995;22:  
272 73-81.
- 273 9. Ware JE, Kosinski M, Dewey JE, Gandek B. How to score and interpret  
274 single-item health status measures: A manual for users of the SF-8 health  
275 survey. Lincoln, RI: Quality Metric Inc.; 2001.
- 276 10. Fukuhara S, Suzukamo Y. Manual of the SF-8 Japanese version. Kyoto:  
277 Institute for Health Outcomes and Process Evaluation Research; 2004 (in  
278 Japanese).

- 279 11. Headache classification subcommittee of the international headache society.  
280 The international classification of headache disorders. 3rd ed. Cephalgia.  
281 2018;38: 1-211.
- 282 12. American Psychiatric Association. Diagnostic and statistical manual of mental  
283 disorders, fifth edition (DSM-5). Washington DC: American Psychiatric  
284 Association; 2013.
- 285 13. American Psychiatric Association. Diagnostic and statistical manual of mental  
286 disorders. Fourth edition, text revision (DSM-IV-TR). Washington DC:  
287 American Psychiatric Association; 2000.
- 288 14. Miyauchi T, Tokura T, Kimura H, Ito M, Umemura E, Sato A, et al. Effect of  
289 antidepressant treatment on plasma levels of neuroinflammation-associated  
290 molecules in patients with somatic symptom disorder with predominant pain  
291 around the orofacial region. *Hum Psychopharmacol Clin Exp*. 2019;34: e2698.
- 292 15. Nakamura M, Yoshimi A, Mouri A, Tokura T, Kimura H, Kishi S, et al.  
293 Duloxetine attenuates pain in association with downregulation of platelet  
294 serotonin transporter in patients with burning mouth syndrome and atypical  
295 odontalgia. *Hum Psychopharmacol Clin Exp*. 2022;7: e2818.

- 296 16. Nagashima W, Kimura H, Ito M, Tokura T, Arao M, Aleksic B, et al.  
297 Effectiveness of duloxetine for the treatment of chronic nonorganic orofacial  
298 pain. *Clin Neuropharmacol*. 2012;35: 273-77.
- 299 17. Kobayashi Y, Nagashima W, Tokura T, Yoshida K, Umemura E, Miyauchi T, et  
300 al. Duloxetine plasma concentrations and its effectiveness in the treatment of  
301 nonorganic chronic pain in the orofacial region. *Clin Neuropharmacol*.  
302 2017;40: 163-8.
- 303 18. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for  
304 measuring depression. *Arch Gen Psychiatry*. 1961;4: 561-71.
- 305 19. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry*.  
306 1960;23: 56-62.
- 307 20. Khan WU, Michelini G, Battaglia M. Twin studies of the covariation of pain  
308 with depression and anxiety: a systematic review and re-evaluation of critical  
309 needs. *Neurosci Biobehav Rev*. 2020;111: 135-48.
- 310 21. Itokazu M, Ito Y, Takigami I, Suzuki A, Ohno K, Ogawa H. Evaluation of  
311 quality of life (SF-8) following treatment with tacrolimus in patients with  
312 rheumatoid arthritis. *Jpn J Rheum Jt Surg*. 2007;26: 403-11.
- 313 22. Yamamoto C, Hyakuta T. Relationship between comprehensive geriatric



- 314 assessment and medication adherence among home-bound elderly stroke  
315 survivors. JJNSR. 2018;41; 741-51.
- 316 23. Callahan LF, Pincus T. A clue from a selfreport questionnaire to distinguish  
317 rheumatoid arthritis from noninflammatory diffuse musculoskeletal pain.  
318 Arthritis Rheum. 1990;33: 1317-22.
- 319 24. Lorish CD, Maisiak R. The face scale: a brief, nonverbal method for assessing  
320 patient mood. Arthritis Rheum. 1986;29: 906-9.
- 321 25. Shueb SS, Nixdorf DR, JohnMT, Alonso BF, Durham J. What is the impact of  
322 acute and chronic orofacial pain on quality of life? J Dent. 2015;43: 1203-10.
- 323 26. Mukoyama N, Nishio N, Kimura H, Kishi S, Tokura T, Kimura H, et al.  
324 Prospective evaluation of health-related quality of life in patients undergoing  
325 anterolateral craniofacial resection with orbital exenteration. J Neurol Surg B  
326 Skull Base. 2020;81: 585-93.

**(A)****(B)**